Pancreatic Cancer
A cancer of the pancreas that is often diagnosed at an advanced stage, where timely specialist evaluation and access to the latest treatment approaches can meaningfully change the care pathway.
- Multidisciplinary tumor board review
- Molecular and genomic testing
- Access to clinical trials
- Most Common In
- Adults over 60
- Most Common Subtype
- Ductal Adenocarcinoma
- Key Mutation
- KRAS (~90%)
- Advanced Therapies
- Targeted Agents, Precision Medicine
Condition Overview
Pancreatic cancer arises from cells of the pancreas, an organ that sits behind the stomach and plays a central role in digestion and blood sugar regulation. The most common form, pancreatic ductal adenocarcinoma (PDAC), develops in the cells lining the pancreatic ducts, while rarer forms include acinar cell carcinoma and pancreatic neuroendocrine tumors.
Because the pancreas is located deep in the abdomen and early symptoms are often vague, many cases are diagnosed after the cancer has already spread locally or to other organs. This makes prompt referral to a specialist team experienced in pancreatic cancer particularly important.
Outcomes and treatment options depend heavily on the stage at diagnosis, the tumor's molecular profile, and whether the cancer is amenable to surgical removal.
Types and Subtypes
Pancreatic tumors are grouped by the cell type from which they arise, which affects both biology and treatment approach.
Symptoms and Signs
Early pancreatic cancer often causes few or no symptoms, which contributes to delayed diagnosis. Symptoms that do appear are frequently nonspecific.
Causes and Risk Factors
The exact cause of most pancreatic cancers is not known, but several factors are associated with increased risk.
Diagnosis and Investigations
Diagnosing pancreatic cancer typically involves imaging to locate and characterize the tumor, followed by tissue sampling to confirm the diagnosis and guide treatment.
Staging and Risk Groups
Pancreatic cancer is staged using the TNM system, but in practice treatment decisions often hinge on whether the tumor can be surgically removed.
Standard Treatment
Treatment is tailored to resectability status, overall health, and the tumor's molecular profile.
Advanced & Emerging Therapies
Research continues into therapies that target the specific molecular drivers of pancreatic cancer and that harness the immune system.
Targeted Therapy
PARP Inhibitors
Used in select patients with BRCA1/2 mutations, particularly as maintenance therapy after initial chemotherapy response.
Precision Medicine
KRAS-Targeted Agents
An active area of drug development targeting KRAS mutations found in most pancreatic cancers; access varies by specific mutation subtype.
Immunotherapy
Checkpoint Inhibitors
Generally limited benefit in pancreatic cancer overall, but can be effective in the rare tumors with mismatch repair deficiency or high microsatellite instability.
Antibody-Drug Conjugate
ADC Platforms
Investigational antibody-drug conjugates are being studied for pancreatic cancer in early-phase trials.
Biomarkers & Precision Medicine
Molecular testing can identify features that influence prognosis and open the door to targeted treatment options or clinical trials.
When to Seek a Second Opinion
Given the complexity of treatment decisions in pancreatic cancer, a second opinion from a high-volume specialist center can meaningfully change the care plan.
Clinical Trials & Research
Prognosis & Outcomes
Outcomes in pancreatic cancer vary considerably depending on stage at diagnosis, resectability, and response to treatment. Advances in surgical technique, systemic therapy, and molecular-guided treatment have changed the outlook for some patient subgroups.
Supportive Care
Supportive care plays a central role in pancreatic cancer treatment, addressing both disease- and treatment-related challenges.
How CancerFax Helps You Explore Treatment Options
CancerFax can help coordinate medical report review, second opinions, and access to specialist pancreatic cancer centers and clinical trials.
Get a free case reviewFrequently Asked Questions
Early pancreatic cancer often causes no symptoms. When symptoms do appear, they commonly include unexplained weight loss, abdominal or back pain, and new or worsening diabetes. Jaundice, or yellowing of the skin and eyes, can occur if the tumor blocks the bile duct.
Most cases are not directly inherited, but a meaningful subset is linked to inherited mutations such as BRCA1, BRCA2, and other genes. Genetic counseling and testing are recommended for patients with a family history of pancreatic, breast, or ovarian cancer.
It means the tumor has some involvement with nearby blood vessels that makes upfront surgery technically difficult, but treatment with chemotherapy first may shrink the tumor enough to allow surgery later.
The Whipple procedure, or pancreaticoduodenectomy, is a major operation that removes the head of the pancreas along with part of the small intestine, bile duct, and sometimes part of the stomach. It is one of the main surgical options for tumors located in the head of the pancreas.
Yes. When surgery is not possible due to the extent of disease, chemotherapy, sometimes combined with radiation, becomes the main treatment approach, with the goal of controlling the cancer and relieving symptoms.
CA 19-9 is a blood marker often elevated in pancreatic cancer. It is not used to diagnose the cancer on its own but can help track how well treatment is working over time.
Yes, for select patients. Those with BRCA1/2 mutations may benefit from PARP inhibitor maintenance therapy, and a small subset of tumors with high microsatellite instability may respond to immunotherapy. Other targeted approaches remain under active investigation.
Supportive care commonly includes nutritional support with pancreatic enzymes, pain management, blood sugar control, and biliary drainage procedures when needed, alongside psychosocial support for patients and families.
Genomic testing can identify mutations such as BRCA1/2 or KRAS subtypes that may open access to targeted therapies or relevant clinical trials, making it an important step in personalizing treatment.
Yes. CancerFax can help you organize and share your medical reports for specialist review, coordinate a second opinion from oncologists experienced in pancreatic cancer, explore access to advanced and targeted therapies, and support cross-border coordination with international treatment centers if that is part of your care plan.
Get Expert Guidance on Your Pancreatic Cancer Diagnosis
Share your medical reports with our team to explore treatment options, second opinions, and access to advanced therapies.